A Study on the Application and Use of Artificial Intelligence to Support Drug Development

被引:51
|
作者
Lamberti, Mary Jo [1 ]
Wilkinson, Michael [1 ]
Donzanti, Bruce A. [2 ]
Wohlhieter, G. Erich [3 ]
Parikh, Sudip [4 ]
Wilkins, Robert G. [5 ]
Getz, Ken [1 ]
机构
[1] Tufts Univ, Sch Med, Tufts Ctr Study Drug Dev, Boston, MA 02111 USA
[2] Genentech Inc, Global Pharmacovigilance Innovat Policy, San Francisco, CA 94080 USA
[3] Amgen Inc, Digital Hlth & Innovat, Thousand Oaks, CA USA
[4] Drug Informat Assoc Amer, Washington, DC USA
[5] QPS Consulting LLC, Ashburn, VA USA
关键词
AI; artificial intelligence; drug development; machine learning; technology;
D O I
10.1016/j.clinthera.2019.05.018
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: The Tufts Center for the Study of Drug Development (CSDD) and the Drug Information Association (DIA) in collaboration with 8 pharmaceutical and biotechnology companies conducted a study examining the adoption and effect of artificial intelligence (AI), such as machine learning, on drug development. The study was conducted to clarify and understand AI adoption across the industry and to gather detailed insights into the spectrum of activities included in the definition of AI. The study investigated and identified analytical platforms and innovations across pharmaceutical and biotechnology companies currently being used or planned for in the future. Methods: A 2-part method was used that comprised in-depth interviews with AI industry experts and a global survey conducted across pharmaceutical and biotechnology organizations. Eleven in-depth interviews focused on use and implementation of AI across drug development. The survey assessed use of AI and included perceptions about current and future use. The survey also examined technology definitions, assessment of organizational and personal AI expertise, and use of partnerships. A total of 402 responses, including data from 217 unique organizations, were analyzed. Findings: Although 7 in 10 respondents reported using AI in some capacity, a wide range of use was reported by AI type. Patient selection and recruitment for clinical studies was the most commonly reported AI activity, with 34 respondents currently using AI for this activity. In addition, identification of medicinal products data gathering was the top activity being piloted or in the planning stages, reported by 49 respondents. The study also revealed that the most significant challenges to AI implementation included staff skills (55%), data structure (52%), and budgets (49%). Nearly 60% of respondents noted planned increases in staff within 1-2 years to support AI use or implementation. Implications: Despite the challenges to AI implementation, the survey revealed that most organizations use AI in some capacity and that it is important to the success of an organization's workforce. Many organizations reported expectations for increasing staff as implementation of AI expands. Further research should examine the changing development landscape as the role of AI evolves. (C) 2019 Elsevier Inc. All rights reserved.
引用
收藏
页码:1414 / 1426
页数:13
相关论文
共 50 条
  • [41] Application of Artificial Intelligence in Drug-Drug Interactions Prediction: A Review
    Zhang, Yuanyuan
    Deng, Zengqian
    Xu, Xiaoyu
    Feng, Yinfei
    Shang, Junliang
    JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2023, 64 (07) : 2158 - 2173
  • [42] Use of artificial intelligence to enhance phenotypic drug discovery
    Malandraki-Miller, Sophia
    Riley, Paul R.
    DRUG DISCOVERY TODAY, 2021, 26 (04) : 887 - 901
  • [43] Artificial intelligence for solving solubility problems in drug development
    Damiati, Safa
    Smith, Norman
    Herrero-Zazo, Maria
    Martini, Luigi
    Lawrence, Jane
    Barlow, David
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2017, 69 : 7 - 7
  • [44] Artificial intelligence and machine learning in drug discovery and development
    Patel V.
    Shah M.
    Intelligent Medicine, 2022, 2 (03): : 134 - 140
  • [45] Artificial Intelligence Effecting a Paradigm Shift in Drug Development
    Rashid, Masturah Bte Mohd Abdul
    SLAS TECHNOLOGY, 2021, 26 (01): : 3 - 15
  • [46] Artificial Intelligence for Drug Development, Precision Medicine, and Healthcare
    Yoon, Frank
    INTERNATIONAL STATISTICAL REVIEW, 2021, 89 (01) : 209 - 209
  • [47] Artificial intelligence utility for drug development: ChatGPT and beyond
    Gurwitz, David
    Shomron, Noam
    DRUG DEVELOPMENT RESEARCH, 2024, 85 (02)
  • [48] The Promise of Artificial Intelligence in Reshaping Anticancer Drug Development
    Papavassiliou, Kostas A.
    Sofianidi, Amalia A.
    Gogou, Vassiliki A.
    Papavassiliou, Athanasios G.
    CELLS, 2024, 13 (20)
  • [49] Artificial intelligence for aging research in cancer drug development
    Shirini, Dorsa
    Schwartz, Lawrence H.
    Dercle, Laurent
    AGING-US, 2023, 15 (22): : 12699 - 12701
  • [50] The Potential Applications of Artificial Intelligence in Drug Discovery and Development
    Farghali, Hassan
    Kutinova Canova, Nikolina
    Arora, Mahak
    PHYSIOLOGICAL RESEARCH, 2021, 70 : S715 - S722